Kytopen和Aldevron通过其协作的CRISPR介导的细胞工程工作流程加速细胞治疗制造-动脉网

Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow

CISION 等信源发布 2025-04-29 22:07



可切换为仅中文







Kytopen Logo (PRNewsfoto/Kytopen)

Kytopen标志 (PRNewsfoto/Kytopen)

Aldevron

阿尔德夫龙

Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies.

凯托彭和阿尔德弗隆宣布合作，通过结合他们的创新技术加速细胞治疗制造。

High transgene expression and improved safety profile of Aldveron's Nanoplasmid

Aldveron的纳米质粒具有高转基因表达和改善的安全性特征

™

vector technology and the gentle gene-delivery of Kytopen's

矢量技术与Kytopen的温和基因递送

Flowfect Tx™ platform

Flowfect Tx™ 平台

with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields.

通过无限规模，共同提供增强的CRISPR介导的T细胞工程，从而实现高产量。

A poster summarizing the data will be presented at ISCT,

一份总结数据的海报将在ISCT上展示，

May 7-10, 2025

2025年5月7日至10日

, in

，在

New Orleans

新奥尔良

。

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

and

和

FARGO, N.D.

法戈，北达科他州

，

April 29, 2025

2025年4月29日

/PRNewswire/ -- Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; today announced, a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers.

/PRNewswire/ -- Kytopen Corp. 是一家提供非病毒、连续流动细胞工程技术研发的领导者，而 Aldevron 是一家为基因编辑、mRNA 疫苗和治疗、病毒基因治疗以及修饰基因治疗领域提供服务的全球领先制造商；双方今日宣布了一项联合营销协议，旨在加强细胞治疗制造商的工作流程解决方案。

The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanoplasmid™ vector technology with Kytopen's Flowfect Tx™ GMP cellular engineering platform in CRISPR-mediated engineering of primary T Cells..

该合作将专注于联合推广通过将Aldveron Nanoplasmid™载体技术与Kytopen的Flowfect Tx™ GMP细胞工程平台相结合，在CRISPR介导的原代T细胞工程中所实现的协同效应。

Aldveron's Nanoplasmid vector offers high transgene expression and improved safety profile while the Flowfect

阿尔德维隆的纳米质粒载体提供高转基因表达和更安全的特性，而Flowfect

continuous flow technology ensures gentle gene delivery with unlimited scale. Together these technologies provide an enhanced CRISPR-mediated T-cell engineering workflow resulting in high yields saving cell therapy developers time in a cost-effective manner.

连续流技术确保了温和的基因递送，并具有无限的规模。这些技术共同提供了一个增强的CRISPR介导的T细胞工程工作流程，从而实现了高产量，节省了细胞治疗开发者的时间，并且具备成本效益。

The two companies created a joint poster of the resulting data that Kypoten will present at the International Society of Cell & Gene Therapy ('ISCT') Annual Meeting,

这两家公司创建了包含相关数据的联合海报，Kypoten 将在国际细胞与基因治疗学会（ISCT）年会上展示。

May 7-10, 2025

2025年5月7日至10日

, in

，在

New Orleans, LA

路易斯安那州新奥尔良市

, highlighting the increase in the overall yield of final drug substance and ease of manufacturing over viral and electroporation technologies. The data will also be featured in Kytopen's Global Showcase Oral Presentation on

，突出了与病毒和电穿孔技术相比，最终药物成分的总产量增加以及制造的便利性。这些数据还将在Kytopen的全球展示口头报告中亮相。

Thursday, May 8

5月8日，星期四

。

'The work with Aldevron is part of a larger, shared commitment to enable advance cell therapies by streamlining workflows to deliver greater yields of healthier cells,' said

“与Aldevron的合作是一项更大、共同承诺的一部分，旨在通过简化工作流程来提高细胞产量和健康度，从而推动先进的细胞疗法发展，”

Kevin Gutshall

凯文·古特肖尔

, Chief Commercial Officer at Kytopen. 'The combination of our technologies provides a GMP process for delivering high-quality CAR-T cells that is now available for use in clinical and commercial applications.'

，Kytopen的首席商务官。“我们技术的结合提供了一种用于输送高质量CAR-T细胞的GMP工艺，现在可用于临床和商业应用。”

'This collaboration continues to demonstrate the superior performance of our Nanoplasmid vectors across novel transfection technologies,' said Anu Codaty, VP of Global Marketing and Strategy for Aldevron. 'The combination of the Nanoplasmid technology with Kytopen's Flowfect

“这次合作继续展示了我们的纳米质粒载体在新型转染技术中的卓越性能，”Aldevron全球营销与战略副总裁Anu Codaty表示。“纳米质粒技术与Kytopen的Flowfect技术的结合...”

cell engineering technology has delivered higher edited-cell yields faster, which will help meet the growing patient demand as the adoption of CRISPR-based therapies accelerates.'

细胞工程技术已提高了编辑细胞的产量，并加快了速度，这将有助于满足随着基于CRISPR的疗法应用加速而日益增长的患者需求。

In addition to the presentations, Kytopen will be available to answer any questions at booth 347 at ISCT.

除了演讲之外，Kytopen还将在ISCT的347号展位解答任何问题。

ISCT Poster Presentation.

ISCT海报展示。

Wednesday, May 7, 2025

2025年5月7日，星期三

, at

，位于

6:00pm

下午6:00

; POSTER BOARD: 1100

; 海报板：1100

CONTINUOUS FLOW TRANSFECTION WITH FLOWFECT

使用FLOWFECT进行连续流动转染

TECHNOLOGY AS AN EFFICIENT, NON-VIRAL TECHNOLOGY FOR SCALABLE CRISPR-MEDIATED ENGINEERING OF PRIMARY T CELLS

技术作为一种高效、非病毒的技术，用于可扩展的CRISPR介导的原代T细胞工程

Global Showcase. 15 min Presentation,

全球展示。15分钟演讲，

Thursday, May 8, 2025

2025年5月8日，星期四

, at

，位于

6:00pm

下午6:00

A FULLY VALIDATED, NON-VIRAL GMP PLATFORM FOR THE MANUFACTURE OF ENGINEERED CELLS AT CLINICAL AND COMMERCIAL SCALE

一个完全经过验证的、非病毒的GMP平台，用于临床和商业规模的工程细胞制造

For further information:

更多信息请访问：

Kytopen:

Investor Contact:

投资者联系方式：

Michael Chiu PhD., CEO

邱迈克尔博士，首席执行官

mchiu@kytopen.com

Business and Corporate Development Contact:

商业和企业发展联系人：

Kevin Gutshall

凯文·古特肖尔

, CCO

，首席文化官

kgutshall@kytopen.com

Aldevron:

阿尔德弗龙：

Ellen Shafer

艾伦·沙弗

, Senior Director of Communications

，高级传播总监

ellen.shafer@aldevron.com

701-219-0333

About Kytopen:

关于Kytopen：

The innovative leader in non-viral, continuous flow cellular engineering technologies, Kytopen, headquartered in

非病毒性、连续流动细胞工程技术的创新领导者，Kytopen，总部位于

Cambridge, Massachusetts

马萨诸塞州剑桥市

, is transforming how cell therapies are manufactured by maximizing yields, delivering hundreds of billions of engineered cells in minutes – faster than any other technology – and thereby accelerating the discovery, development, and manufacture of advanced engineered cell therapies. Its Flowfect

，正在通过最大化产量来改变细胞疗法的制造方式，能够在几分钟内交付数千亿个工程细胞——比任何其他技术都快——从而加速先进工程细胞疗法的发现、开发和制造。其Flowfect

cellular engineering technology is highly tunable, gentle on cells, and has demonstrated performance across a range of cell types, payloads, and therapeutic applications. Kytopen has recently disclosed strategic partnerships with industry-leading biotechnology companies, contract development and manufacturing organizations (CDMOs), and cell therapy-focused medical centers.

细胞工程技术具有高度可调性，对细胞温和，并且已经在多种细胞类型、载荷和治疗应用中展示了性能。Kytopen近期公布了与行业领先的生物技术公司、合同开发和制造组织（CDMO）以及专注于细胞治疗的医学中心的战略合作关系。

Kytopen continues to engage strategic partners and is committed to enabling their partners' success by providing innovative technology and developing close collaborative relationships to bring lifesaving, next generation cell therapies to patients worldwide. .

Kytopen持续与战略伙伴合作，致力于通过提供创新技术和发展紧密的协作关系，助力合作伙伴取得成功，将挽救生命的下一代细胞疗法带给全球患者。

www.kytopen.com

About Aldevron

关于Aldevron

Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, RNA, proteins, enzymes, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in

阿尔德夫隆是一家领先的制造合作伙伴，生产用于疫苗、基因和细胞疗法、免疫疗法及其他治疗手段开发的高质量质粒DNA、RNA、蛋白质、酶及其他关键成分。总部位于

Fargo, North Dakota

法戈，北达科他州

, and as a part of the Danaher Corporation (NYSE:

，作为丹纳赫集团（纽约证券交易所代码：的一部分

DHR

) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit

）作为全球科技公司家族的一员，Aldevron 支持数千名科学家，他们正在为数百万人开发革命性的救命疗法。要了解更多关于 Aldevron 如何推动生物科学发展的信息，请访问

www.aldevron.com/about-us

。

SOURCE Kytopen

来源 Kytopen

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &